Moderna Says New Vaccine Targets Omicron

Biotechnology company Moderna said its new COVID-19 vaccine targets Omicron variants, promising “more durable protection” than the previous booster.

Moderna said Wednesday that the new vaccine booster passed the clinical trial, neutralizing antibody response against the Omicron and older COVID-19 variants.

According to Moderna, 437 participants in the trial of the “bivalent” booster showed positive toleration over the 50 micrograms (0.05 milligram) dose of the vaccine.

Stéphane Bancel, Chief Executive Officer of Moderna, referred to the new vaccine as the “lead candidate” for COVID-19 boosters this fall.

Moderna said the bivalent booster is safe but has the same side effects as the previous booster, Spikevax.

Clinical trials of Spikevax showed side effects that include swelling and pain in the arm of injection, fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, and fever. 

Bancel said the biotech company would submit the new vaccine to regulators for review in the coming weeks. He said Moderna hopes to make the new vaccine available in late summer. 

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.